Moolec Science (MLEC) Operating Leases (2024 - 2025)
Moolec Science (MLEC) reported Operating Leases of $117463.0 for Q2 2025, down 98.96% on a YoY basis from $11.3 million in Q2 2024, and down 98.96% sequentially from $11.3 million in Q2 2024.
Moolec Science (MLEC) Operating Leases (2024 - 2025) Analysis & Trends
Moolec Science (MLEC) has 2 years of Operating Leases data on file, last reported at $117463.0 in Q2 2025.
- For the quarter ending Q2 2025, Operating Leases fell 98.96% year-over-year to $117463.0; the trailing twelve-month figure through Jun 2025 stood at $117463.0 (down 98.96% YoY), and the FY2025 full-year result was $117463.0, down 98.96% from the prior year.
- Operating Leases fell to $117463.0 in Q2 2025, from $11.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $11.3 million in Q2 2024 to a low of $117463.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Moolec Science | 5.35 Bn | 5.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 117,463.00 |
| Jun 30, 2024 | 11.28 Mn |